MaveriX boasts a deep pipeline of Conditionally Activated-Small Molecule Drug Conjugate (CA-SMDC) product candidates for the treatment of a broad range of solid tumors. Our differentiated technology approach has been conceived with the aim of revolutionizing targeted cancer therapy by challenging the limitations of current chemotherapy and immunotherapy.
Program
Nucleoside analog
Indications
Multiple Solid Tumors
Phase 1a Dose Escalation
Status:
Preclinical/ IND
Program
Nucleoside phosphate
Indications
Multiple Solid Tumors
Phase 1a Dose Escalation
Status:
Preclinical/ IND
Program
Nucleotide analog
Indications
Metastatic Cancers
mCRC
Phase 1a Dose Escalation
Monotherapy
Status:
Preclinical/ IND
Program
Auristatin tyramine
Indications
Metastatic Cancers
mUC
Phase 1a Dose Escalation
Monotherapy
Status:
Preclinical/ IND
Program
Camptothecin analog
Indications
Metastatic Cancers
mBC
Phase 1a Dose Escalation
Monotherapy
Status:
Preclinical/ IND
Program
TLR7/8-Agonist
Indications
Phase 1a Dose Escalation
Undisclosed
Status:
Preclinical/ IND
Program
STING-Agonist
Indications
Phase 1a Dose Escalation
Undisclosed
Status:
Preclinical/ IND